Research programme: sexual dysfunction therapeutics - S1 Biopharma
Alternative Names: S1P-401Latest Information Update: 31 Jul 2024
At a glance
- Originator S1 Pharmaceuticals
- Developer S1 Biopharma
- Class
- Mechanism of Action Central nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anorgasmia; Decreased libido; Female sexual dysfunction; Male sexual dysfunction
Most Recent Events
- 31 Jul 2024 Research programme: sexual dysfunction therapeutics is still in preclinical development for Decreased libido in USA
- 31 Jul 2024 Research programme: sexual dysfunction therapeutics is still in preclinical development for Anorgasmia in USA
- 31 Jul 2024 Research programme: sexual dysfunction therapeutics is still in preclinical development for Female sexual dysfunction in USA